Skip to content

COMPARISON OF THE EFFICACY OF THREE VERSUS MORE THAN THREE DOSES OF INTRAPLEURAL STREPTOKINASE IN CHILDREN SUFFERING WITH EMPYEMA

COMPARISON OF THREE VERSUS MORE THAN THREE DOSES OF INTRAPLEURAL STREPTOKINASE IN EMPYEMA IN CHILDREN - MISTY TRIAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/03/024287
Enrollment
60
Registered
2020-03-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J86- Pyothorax

Interventions

Intervention1: Intrapleural Streptokinase group: In the intrapleural streptokinase group (i.e. group A1 and B1)three additional doses of Intrapleural Streptokinase would be administered daily over thr

Sponsors

PGIMER Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children less than 18 years age with empyema. Empyema will be defined as â??presence of pus on a diagnostic pleural tap in children with clinical and/or radiological features consistent with pneumonia and parapneumonic pleural effusionâ??.

Exclusion criteria

Exclusion criteria: 1.Prior chest tube drainage with use of intrapleural fibrinolytics or any surgical intervention 2.Contra-indications to fibrinolytic therapy viz (a)Known Coagulopathy or Bleeding disorders or (b)Confirmed Pneumothorax or bronchopleural fistula (c)Head trauma during the preceding 2 weeks

Design outcomes

Primary

MeasureTime frame
Primary objective To compare the efficacy of three doses versus more than three doses of intrapleural streptokinase in management of empyema in children. Timepoint: At discharge

Secondary

MeasureTime frame
To compare the safety, markers of pulmonary function and radiological features in three doses versus more than three doses of intrapleural streptokinase in management of empyema in children.Timepoint: Three months after discharge

Countries

India

Contacts

Public ContactKamal Kumar Singhal

PGIMER, Chandigarh.

dr.joseph.l.mathew@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026